Science & technology
Our pipeline
COVID-19 Omicron

Novavax COVID-19 Omicron vaccine

COVID-19 Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
COVID-19
 
Preclinical
Matrix-M™ adjuvant
Therapeutic area
Respiratory diseases
Infectious disease
COVID-19
Status
 
Preclinical
Technology
Matrix-M™ adjuvant

About the candidate

As the SARS-CoV-2 virus continues to evolve, Novavax is evaluating a variant strain vaccine based on the Omicron (B.1.1.529) Variant of Concern (VOC).

In December 2021, Novavax began developing an Omicron-specific variant vaccine and within weeks we initiated GMP manufacturing. Novavax expects to begin clinical studies of this candidate in Q2 2022.

Clinical trials
More about the disease